These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10712917)

  • 1. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects.
    Prendergast GC
    Curr Opin Cell Biol; 2000 Apr; 12(2):166-73. PubMed ID: 10712917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
    Prendergast GC; Oliff A
    Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors.
    Liu A; Prendergast GC
    FEBS Lett; 2000 Sep; 481(3):205-8. PubMed ID: 11007964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
    Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
    Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RhoB and the cellular response to farnesyltransferase inhibitors: the search for clues to cell death mechanisms.
    Bernhard EJ
    Cancer Biol Ther; 2003; 2(3):281-2. PubMed ID: 12878866
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF; Prendergast GC
    Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.
    Prendergast GC
    Histol Histopathol; 2001 Jan; 16(1):269-75. PubMed ID: 11193202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.
    Pan J; She M; Xu ZX; Sun L; Yeung SC
    Cancer Res; 2005 May; 65(9):3671-81. PubMed ID: 15867362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development.
    Adini I; Rabinovitz I; Sun JF; Prendergast GC; Benjamin LE
    Genes Dev; 2003 Nov; 17(21):2721-32. PubMed ID: 14597666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors: mechanism and applications.
    Prendergast GC; Rane N
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2105-16. PubMed ID: 11772308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
    Du W; Prendergast GC
    Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actin' up: RhoB in cancer and apoptosis.
    Prendergast GC
    Nat Rev Cancer; 2001 Nov; 1(2):162-8. PubMed ID: 11905808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitors: targeting the molecular basis of cancer.
    Oliff A
    Biochim Biophys Acta; 1999 May; 1423(3):C19-30. PubMed ID: 10382537
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB.
    Kamasani U; Liu AX; Prendergast GC
    Cancer Biol Ther; 2003; 2(3):273-80. PubMed ID: 12878865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
    Delarue FL; Adnane J; Joshi B; Blaskovich MA; Wang DA; Hawker J; Bizouarn F; Ohkanda J; Zhu K; Hamilton AD; Chellappan S; Sebti SM
    Oncogene; 2007 Feb; 26(5):633-40. PubMed ID: 16909123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
    Thomas X; Elhamri M
    Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
    Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
    Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.